Dixon Mitchell Investment Counsel Inc. Has $33.73 Million Holdings in Danaher Co. (NYSE:DHR)

Dixon Mitchell Investment Counsel Inc. boosted its holdings in Danaher Co. (NYSE:DHR - Free Report) by 11.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 146,781 shares of the conglomerate's stock after acquiring an additional 15,341 shares during the quarter. Danaher accounts for about 1.6% of Dixon Mitchell Investment Counsel Inc.'s investment portfolio, making the stock its 25th biggest position. Dixon Mitchell Investment Counsel Inc.'s holdings in Danaher were worth $33,733,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the stock. Teachers Insurance & Annuity Association of America bought a new stake in shares of Danaher during the third quarter worth $39,000. MidAtlantic Capital Management Inc. acquired a new position in Danaher in the third quarter valued at approximately $40,000. FSA Wealth Management LLC bought a new position in shares of Danaher in the 3rd quarter worth $50,000. Darwin Wealth Management LLC acquired a new position in shares of Danaher during the 3rd quarter worth about $55,000. Finally, Modus Advisors LLC bought a new stake in Danaher in the fourth quarter valued at approximately $56,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Up 0.1 %

Shares of DHR opened at $237.78 on Thursday. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. Danaher Co. has a 12 month low of $222.53 and a 12 month high of $281.70. The firm's 50 day moving average is $235.27 and its 200-day moving average is $253.56. The stock has a market capitalization of $171.74 billion, a PE ratio of 45.38, a P/E/G ratio of 4.23 and a beta of 0.83.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping analysts' consensus estimates of $1.57 by $0.14. The firm had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The company's revenue was up 3.1% on a year-over-year basis. During the same quarter last year, the company earned $2.02 EPS. Equities research analysts forecast that Danaher Co. will post 7.49 EPS for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. The ex-dividend date is Friday, December 27th. Danaher's dividend payout ratio (DPR) is presently 20.61%.

Analyst Ratings Changes

Several brokerages have commented on DHR. Barclays dropped their target price on shares of Danaher from $285.00 to $275.00 and set an "equal weight" rating on the stock in a report on Wednesday, October 23rd. Guggenheim assumed coverage on Danaher in a research report on Thursday, December 19th. They set a "buy" rating and a $275.00 price target on the stock. Scotiabank assumed coverage on Danaher in a report on Monday, December 23rd. They issued a "sector perform" rating and a $265.00 price objective for the company. Raymond James lowered their target price on shares of Danaher from $310.00 to $300.00 and set an "outperform" rating on the stock in a report on Wednesday, October 23rd. Finally, Stifel Nicolaus increased their price target on shares of Danaher from $250.00 to $265.00 and gave the company a "hold" rating in a research note on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $286.80.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.